| Assessment Status | Rapid Review Complete |
| HTA ID | 21005 |
| Drug | Autologous anti-CD19-transduced CD3+ cells |
| Brand | Tecartus® |
| Indication | For the treatment of adult patients with relapsed or refractory mantle cell lymphoma after two or more lines of systemic therapy including a Bruton’s tyrosine kinase inhibitor. |
| Assessment Process | |
| Rapid review commissioned | 03/03/2021 |
| Rapid review completed | 22/03/2021 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of autologous anti-CD19-transduced CD3+ cells compared with the current standard of care |
| Full pharmacoeconomic assessment commissioned by HSE | 31/03/2021 |
The company has not submitted a HTA dossier to the NCPE, therefore the cost effectiveness of the technology could not be proven.